Structured evidence table for Coconut Oil Cholesterol Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Coconut Oil Cholesterol Randomized Trial | This narrative review integrates observational, clinical, and mechanistic evidence across circulating lipids and lipoproteins, glucose homeostasis, inflammation and vascular markers, adiposity, and hepatic endpoints. | 3 | Destaillats F (2026) | Palmitoleic (16:1 n-7) acid and metabolic health: integrating observational, clinical, and mechanistic evidence. |
| Coconut Oil Cholesterol Randomized Trial | Overall, current evidence supports cautious interpretation: POA is biologically interesting, but clinically meaningful benefits of purified POA supplementation remain unproven and require adequately powered trials in well-characterized at-risk populations. | 3 | Destaillats F (2026) | Palmitoleic (16:1 n-7) acid and metabolic health: integrating observational, clinical, and mechanistic evidence. |
| Coconut Oil Cholesterol Randomized Trial | Palmitoleic acid (POA; 16:1 n-7) has been proposed as a lipokine linking adipose tissue, liver, and skeletal muscle metabolism, but its relevance to human metabolic health remains uncertain. | 3 | Destaillats F (2026) | Palmitoleic (16:1 n-7) acid and metabolic health: integrating observational, clinical, and mechanistic evidence. |
| Coconut Oil Cholesterol Randomized Trial | Virgin coconut oil: A comprehensive review of its health impacts and functional food applications | 3 | Khan I (2026) | Virgin coconut oil: A comprehensive review of its health impacts and functional food applications |
Source documents